- Report
- May 2025
- 183 Pages
Global
From €3175EUR$3,545USD£2,707GBP
€3528EUR$3,939USD£3,008GBP
- Report
- June 2025
- 372 Pages
Global
From €5240EUR$5,850USD£4,467GBP
- Report
- June 2025
- 50 Pages
Global
From €2374EUR$2,650USD£2,023GBP
- Report
- April 2025
- 130 Pages
Global
From €3910EUR$4,365USD£3,333GBP
€4344EUR$4,850USD£3,703GBP
From €4389EUR$4,900USD£3,741GBP
- Report
- May 2025
- 184 Pages
Global
From €3175EUR$3,545USD£2,707GBP
€3528EUR$3,939USD£3,008GBP
- Report
- May 2025
- 193 Pages
Global
From €3175EUR$3,545USD£2,707GBP
€3528EUR$3,939USD£3,008GBP
- Report
- May 2025
- 195 Pages
Global
From €3175EUR$3,545USD£2,707GBP
€3528EUR$3,939USD£3,008GBP
- Report
- May 2025
- 191 Pages
Global
From €3175EUR$3,545USD£2,707GBP
€3528EUR$3,939USD£3,008GBP
- Report
- April 2025
- 200 Pages
Global
From €4022EUR$4,490USD£3,428GBP
- Report
- March 2025
- 200 Pages
Global
From €4022EUR$4,490USD£3,428GBP
- Report
- February 2025
- 200 Pages
Global
From €4022EUR$4,490USD£3,428GBP
- Report
- February 2025
- 200 Pages
Global
From €4022EUR$4,490USD£3,428GBP
- Report
- June 2025
- 381 Pages
Global
From €5240EUR$5,850USD£4,467GBP
- Report
- January 2025
- 135 Pages
Global
From €2686EUR$2,999USD£2,290GBP
- Report
- May 2025
- 150 Pages
Global
From €2417EUR$2,699USD£2,061GBP
- Report
- May 2025
- 150 Pages
Global
From €2417EUR$2,699USD£2,061GBP
- Drug Pipelines
- August 2024
- 150 Pages
Global
From €2498EUR$2,789USD£2,129GBP
- Report
- October 2024
- 210 Pages
Global
From €7121EUR$7,950USD£6,070GBP
- Clinical Trials
- April 2025
- 60 Pages
Global
From €1344EUR$1,500USD£1,145GBP

Pregabalin is a drug used to treat a variety of conditions related to the central nervous system, including epilepsy, neuropathic pain, fibromyalgia, and generalized anxiety disorder. It is a gamma-aminobutyric acid (GABA) analog that works by binding to certain calcium channels in the brain, reducing the release of neurotransmitters that can cause pain and anxiety. Pregabalin is available in both oral and injectable forms, and is often prescribed in combination with other medications.
Pregabalin is a relatively new drug, having been approved by the US Food and Drug Administration in 2004. Since then, it has become a popular treatment option for many conditions related to the central nervous system. It is generally well-tolerated and has fewer side effects than other drugs used to treat similar conditions.
Some of the companies in the Pregabalin market include Pfizer, Mylan, Teva Pharmaceuticals, and Sun Pharmaceuticals. Show Less Read more